Published in Pharma Law Weekly, May 23rd, 2006
In a recently published article, researchers in Brazil conducted a study "To evaluate the effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer. In this double-blind, placebo-controlled study, 79 patients with cervical cancer were randomized to receive bethanechol (30 mg/day), cisapride (30 mg/day), bethanechol combined with cisapride (same doses) and placebo."
"Urodynamic study was performed, including flowmetry, cystometry, pressure-flow study and urethral pressure profile before radical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly